About Verva
Verva Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company developing novel therapies to treat diabetes and to prevent and treat obesity. Verva's lead product VVP808 is a non-thiazolidinedione insulin sensitizer entering phase 1b/2a clinical safety and efficacy testing in type 2 diabetes. VVP808 was previously approved in North America in an unrelated indication; its unexpected anti-diabetic activity was identified by Verva using the MRU-developed GES platform. Verva's pipeline includes: (i) an accelerated discovery program developing next-generation diabetes therapies based on VVP808 structure and mode-of-action; (ii) expansion of the GES platform to discover new types of optimized diabetes therapies; and (iii) preclinical proof-of-concept with two obesity-focused technologies that block de novo fat formation. Further information can be found on the company's website www.vervapharma.com.
